Abstract
Clinical utility of serum free light chains (sFLC) and heavy chain (HLC) IgM were assessed, using Freelite and Hevylite assays in 70 WM patients. The result showed that median involved (i) sFLC -kappa and -lambda were 45.6 and 78.3mg/ L respectively; median sFLC (kappa+lambda) was 67.4 mg/ L. While, median FLCR (involved/uninvolved FLC ratios) were 2.7 and 6.9 in ikappa- and ilambda -restricted patients respectively. Moreover, increased isFLC, sFLC (kappa+lambda) and FLCR were correlated significantly with shorter time to first treatment (TFT) and adverse survival (OVS). Median iIgM-kappa and iIgM -lambda were 25.4 and 34.8g/L respectively; median HLCR (involved/uninvolved HLC ratios) were 185.5 and 101.9 in kappa- and lambda- restricted patients respectively. In addition, the increased iHLC and HLCR correlated significantly with shorter TFT. Hence, sFLC and HLC measurements appeared to be both prognostic in WM.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
